Clinical Trials Browser

Phase 2 × Biliary Tract Neoplasms × surufatinib × Clear all

NCT06531291 2024-07-31

Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation

Phase 2 Not yet recruiting

Gastrointestinal

Biliary Tract Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms

NCT02966821 2019-02-27

Study of Surufatinib as Second-line Treatment in Patients With Biliary Tract Carcinoma

Phase 2 Completed

Gastrointestinal

Biliary Tract Neoplasms